How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad

We love to hear from our listeners. Send us a message.Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision medicine is headed as researchers pursue more effective treatments for patients with difficult-to-treat solid tumors, and more.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn